Advertisement

Internal and Emergency Medicine

, Volume 14, Issue 8, pp 1217–1231 | Cite as

Aspirin in primary prevention: the triumph of clinical judgement over complex equations

  • Francesca SantilliEmail author
  • Paola Simeone
IM - REVIEW
  • 186 Downloads

Abstract

Aspirin, in 2017, has celebrated its 120th birthday. The efficacy and safety of low-dose aspirin in secondary prevention of cardiovascular disease is well supported by many studies, instead in primary prevention it remains controversial, especially in the aftermath of the publication in 2018 of three novel primary prevention randomized clinical trials, showing that the benefit of low-dose aspirin, although additive to that of statin, is counterbalanced by an excess of (mainly gastrointestinal) bleeding events. The signal for a net benefit seems to be even more controversial in the elderly starting aspirin after the age of 70 years. While international guidelines have promptly downgraded their recommendations to more conservative indications, the practicing clinician is called to make the effort to individualize the treatment, after careful evaluation of the haemorrhagic risk vis-a-vis the risk to develop, in the mid-term and long-term follow-up, major cardiovascular events or cancer. This is a particularly complex task, given the different immediate and long-term impact of diverse outcomes on health, the dynamic nature over time of the benefit/risk balance, prompting periodic re-assessments of its indication, and the interindividual variability in aspirin response. The chemopreventive properties of aspirin, anticipated by a large body of epidemiological and mechanistic evidence, are awaiting their final confirmation by the long-term follow-up of the latest trials specifically designed to assess this endpoint, with the expectation to subvert the delicate benefit/risk balance of aspirin in primary prevention. This review is intended to provide an interpretation of past and current evidence to guide clinical decision making on the contemporary patient.

Keywords

Aspirin Primary prevention Clinical trials Cancer Aspirin responsiveness 

Abbreviations

COX-1

Cyclooxygenase

TXA2

Thromboxane A2

MI

Myocardial infarction

PGI2

Prostacyclin

NNT

Number needed to treat

NNH

Number needed to harm

ASCVD

Atherosclerotic cardiovascular disease

CRC

Colon-rectal cancer

DM

Diabetes mellitus

NSAIDs

Nonsteroidal antiinflammatory drugs

ACS

Acute coronary syndrome

GI

Gastrointestinal

RCT

Randomized controlled trial

EMT

Epithelial mesenchymal transition

Notes

Acknowledgements

The authors wish to thank Professor Carlo Patrono for helpful and constructive discussion.

Funding

This study was supported by a grant from the Italian Ministry of Health (COD WF GR 2011-02350450).

Compliance with ethical standards

Conflict of interest

FS has received lecture fees from Bayer.

Statements on human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this study, formal consent was not required.

References

  1. 1.
    Montinari MR, Minelli S, De Caterina R (2018) The first 3500 years of aspirin history from its roots—a concise summary. Vascul Pharmacol S1537–Ss1891:30354–30359.  https://doi.org/10.1016/j.vph.2018.10.008 CrossRefGoogle Scholar
  2. 2.
    Quick AJ (1968) Bleeding time after aspirin ingestion. Lancet 1:50CrossRefGoogle Scholar
  3. 3.
    Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373–2383CrossRefGoogle Scholar
  4. 4.
    Davì G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357:2482–2494CrossRefGoogle Scholar
  5. 5.
    Lanas A, Bajador E, Serrano P, Fuentes J, Carreño S, Guardia J, Sanz M, Montoro M, Sáinz R (2000) Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343:834–839CrossRefGoogle Scholar
  6. 6.
    Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Scirica BM, Murphy SA, Cannon CP, Investigators COGENT (2010) Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 363:1909–1917.  https://doi.org/10.1056/NEJMoa1007964 CrossRefPubMedGoogle Scholar
  7. 7.
    Li L, Geraghty OC, Mehta Z, Rothwell PM; Oxford Vascular Study (2017) Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 390:490–499.  https://doi.org/10.1016/S0140-6736(17)30770-5 CrossRefGoogle Scholar
  8. 8.
    Antithrombotic Trialists’ Collaboration (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849–1860.  https://doi.org/10.1016/S0140-6736(09)60503-1 CrossRefGoogle Scholar
  9. 9.
    Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81–106CrossRefGoogle Scholar
  10. 10.
    Antithrombotic Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71–86CrossRefGoogle Scholar
  11. 11.
    Smith SC Jr, Benjamin EJ, Bonow RO et al (2011) World Heart Federation and the Preventive Cardiovascular Nurses Association. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 124:2458–2473.  https://doi.org/10.1161/CIR.0b013e318235eb4d CrossRefPubMedGoogle Scholar
  12. 12.
    Piepoli MF, Hoes AW, Agewall S et al (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The sixth joint task force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). Eur Heart J 37:2315–2381.  https://doi.org/10.1093/eurheartj/ehw106 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Ardoino I, Rossio R, Di Blanca D, Investigators REPOSI et al (2017) Appropriateness of antiplatelet therapy for primary and secondary cardio- and cerebrovascular prevention in acutely hospitalized older people. Br J Clin Pharmacol 83:2528–2540.  https://doi.org/10.1111/bcp.13355 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Raber I, McCarthy CP, Vaduganathan M et al (2019) The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet 393:2155–2167.  https://doi.org/10.1016/S0140-6736(19)30541-0 CrossRefPubMedGoogle Scholar
  15. 15.
    Peto R, Gray R, Collins R et al (1988) Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 296:313–316CrossRefGoogle Scholar
  16. 16.
    Steering Committee of the Physicians’ Health Study Research Group (1989) Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 321:129–135CrossRefGoogle Scholar
  17. 17.
    The Medical Research Council’s General Practice Research Framework (1998) Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351:233–241CrossRefGoogle Scholar
  18. 18.
    Hansson L, Zanchetti A, Carruthers SG et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 351:1755–1762CrossRefGoogle Scholar
  19. 19.
    Collaborative Group of the Primary Prevention Project (2001) Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 357:89–95CrossRefGoogle Scholar
  20. 20.
    Ridker PM, Cook NR, Lee IM et al (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352:1293–1304CrossRefGoogle Scholar
  21. 21.
    Ogawa H, Nakayama M, Morimoto T et al (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300:2134–2141.  https://doi.org/10.1001/jama.2008.623 CrossRefPubMedGoogle Scholar
  22. 22.
    Belch J, MacCuish A, Campbell I et al (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337:a1840.  https://doi.org/10.1136/bmj.a1840 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Fowkes FG, Price JF, Stewart MC et al (2010) Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303:841–848.  https://doi.org/10.1001/jama.2010.221 CrossRefPubMedGoogle Scholar
  24. 24.
    Ikeda Y, Shimada K, Teramoto T et al (2014) Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 312:2510–2520.  https://doi.org/10.1001/jama.2014.15690 CrossRefPubMedGoogle Scholar
  25. 25.
    Bibbins-Domingo K (2016) Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 164:836–845.  https://doi.org/10.7326/M16-0577 CrossRefPubMedGoogle Scholar
  26. 26.
    Fox CS, Golden SH, Anderson C et al (2015) Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 38:1777–1803.  https://doi.org/10.2337/dci15-0012 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, Howard G, Pearson TA, Rothwell PM, Ruilope LM, Tendera M, Tognoni G (2018) ARRIVE Executive Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 392:1036–1046.  https://doi.org/10.1016/S0140-6736(18)31924-X CrossRefPubMedGoogle Scholar
  28. 28.
    Capodanno D, Angiolillo DJ (2018) Aspirin for primary prevention of cardiovascular disease. Lancet 392(10152):988–990.  https://doi.org/10.1016/S0140-6736(18)31990-1 CrossRefPubMedGoogle Scholar
  29. 29.
    ASCEND Study Collaborative Group, Bowman L, Mafham M, et al (2018) Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med 379:1529–1539. doi: 10.1056/nejmoa1804988.Google Scholar
  30. 30.
    Diabetes Care (2019) Cardiovascular disease and risk management: standards of medical care in diabetes 2019. 42(Suppl 1): S103–S123. doi: 10.2337/dc19-S010.Google Scholar
  31. 31.
    McNeil JJ, Wolfe R, Woods RL et al (2018) Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med 379:1509–1518.  https://doi.org/10.1056/nejmoa1805819 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    McNeil JJ, Woods RL, Nelson MR et al (2018) Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med 379:1499–1508.  https://doi.org/10.1056/NEJMoa1800722 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    McNeil JJ, Nelson MR, Woods RL et al (2018) Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med 379:1519–1528.  https://doi.org/10.1056/NEJMoa1803955 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Ridker PM (2018) Should aspirin be used for primary prevention in the post-statin era? N Engl J Med 379:1572–1574.  https://doi.org/10.1056/NEJMe1812000 CrossRefPubMedGoogle Scholar
  35. 35.
    Zheng SL, Roddick AJ (2019) Association of aspirin use for primary prevention with cardiovascular events and bleeding events: a systematic review and meta-analysis. JAMA 321:277–287.  https://doi.org/10.1001/jama.2018.20578 CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA (2019) Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J 40:607–617.  https://doi.org/10.1093/eurheartj/ehy813 CrossRefPubMedGoogle Scholar
  37. 37.
    Zheng SL, Chan FT, Maclean E, Jayakumar S, Nabeebaccus AA (2016) Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review. Open Heart 3(2):e000449.  https://doi.org/10.1136/openhrt-2016-000449 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Serebruany V, Pokov I, Kuliczkowski W, Chesebro J, Badimon J (2008) Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 100:76–82.  https://doi.org/10.1160/TH08-03-0136 CrossRefPubMedGoogle Scholar
  39. 39.
    Rocca B, Patrono C (2005) Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 3:1597–1602CrossRefGoogle Scholar
  40. 40.
    Abdelaziz HK, Saad M, Pothineni NVK et al (2019) Aspirin for primary prevention of cardiovascular events. J Am Coll Cardiol 73:2915–2929.  https://doi.org/10.1016/j.jacc.2019.03.501 CrossRefPubMedGoogle Scholar
  41. 41.
    Simeone P, Boccatonda A, Liani R, Santilli F (2018) Significance of urinary 11-dehydro-thromboxane b2 in age-related diseases: focus on atherothrombosis. Ageing Res Rev 48:51–78.  https://doi.org/10.1016/j.arr.2018.09.004 CrossRefPubMedGoogle Scholar
  42. 42.
    Santilli F, Pignatelli P, Violi F, Davi G (2015) Aspirin for primary prevention in diabetes mellitus: from the calculation of cardiovascular risk and risk/benefit profile to personalised treatment. Thromb Haemost 114:876–882.  https://doi.org/10.1160/TH15-03-0202 CrossRefPubMedGoogle Scholar
  43. 43.
    Santilli F, Lapenna D, La Barba S, Davì G (2015) Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus. Free Radic Biol Med 80:101–110.  https://doi.org/10.1016/j.freeradbiomed.2014.12.010 CrossRefPubMedGoogle Scholar
  44. 44.
    Rocca B, Santilli F, Pitocco D et al (2012) The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 10:1220–1230.  https://doi.org/10.1111/j.1538-7836.2012.04723.x CrossRefPubMedGoogle Scholar
  45. 45.
    Santilli F, Simeone P, Liani R (2019) The role of platelets in diabetes mellitus. In: Michelson AD, Cattaneo M, Frelinger AL, Newman PJ (eds) Platelets fouth edition. ElsevierGoogle Scholar
  46. 46.
    Rothwell PM, Cook NR, Gaziano JM et al (2018) Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 392:387–399.  https://doi.org/10.1016/S0140-6736(18)31133-4 CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Petrucci G, Zaccardi F, Giaretta A et al (2019) Obesity is associated with impaired responsiveness to once-daily low-dose aspirin and in vivo platelet activation. J Thromb Haemost 17:885–895.  https://doi.org/10.1111/jth.14445 CrossRefPubMedGoogle Scholar
  48. 48.
    Johnston A, Jones WS, Hernandez AF (2016) The ADAPTABLE trial and aspirin dosing in secondary prevention for patients with coronary artery disease. Curr Cardiol Rep 18:81.  https://doi.org/10.1007/s11886-016-0749-2 CrossRefPubMedGoogle Scholar
  49. 49.
    Kune GA, Kune S, Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne colorectal cancer study. Cancer Res 48:4399–4404PubMedGoogle Scholar
  50. 50.
    Algra AM, Rothwell PM (2012) Effects of regular aspirin on long-term cancer incidence and metastasis: a systemic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 13:518–527.  https://doi.org/10.1016/S1470-2045(12)70112-2 CrossRefPubMedGoogle Scholar
  51. 51.
    Cole BF, Logan RF, Halabi S et al (2009) Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 101:256–266.  https://doi.org/10.1093/jnci/djn485 CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Burn J, Bishop DT, Mecklin JP, CAPP2 Investigators et al (2008) Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 359:2567–2578.  https://doi.org/10.1056/NEJMoa0801297 CrossRefPubMedGoogle Scholar
  53. 53.
    Burn J, Gerdes AM, Macrae F, CAPP2 Investigators et al (2011) Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2081–2087.  https://doi.org/10.1016/S0140-6736(11)61049-0 CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Rothwell PM, Price JF, Fowkes FG et al (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379:1602–1612.  https://doi.org/10.1016/S0140-6736(11)61720-0 CrossRefPubMedGoogle Scholar
  55. 55.
    Menter DG, Dubois RN (2012) Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol 2012:723419.  https://doi.org/10.1155/2012/723419 CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Zelenay S, van der Veen AG, Böttcher JP et al (2015) Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162:1257–1270.  https://doi.org/10.1016/j.cell.2015.08.015 CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Eberhart CE, Coffey RJ, Radhika A et al (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183–1188CrossRefGoogle Scholar
  58. 58.
    Chan AT, Arber N, Burn J et al (2012) Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) 5:164–178.  https://doi.org/10.1158/1940-6207.Capr-11-0391 CrossRefGoogle Scholar
  59. 59.
    Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252–266CrossRefGoogle Scholar
  60. 60.
    Flossmann E, Rothwell PM, British Doctors Aspirin Trial, and the UK-TIA Aspirin Trial (2007) Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369:1603–1613CrossRefGoogle Scholar
  61. 61.
    Rothwell PM, Fowkes FG, Belch JF et al (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:31–41.  https://doi.org/10.1016/S0140-6736(10)62110-1 CrossRefPubMedGoogle Scholar
  62. 62.
    Clarke RJ, Mayo G, Price P et al (1991) Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 325:1137–1141CrossRefGoogle Scholar
  63. 63.
    Patrignani P, Sacco A, Sostres C et al (2016) Direct evidence for long-lasting acetylation of cyclooxygenase-1 associated with reduction of colorectal mucosa prostaglandin E2 levels and ribosomal protein S6 phosphorylation by low-dose aspirin in subjects undergoing colorectal cancer screening. Gastroenterology 150(Suppl 1):S211CrossRefGoogle Scholar
  64. 64.
    Kanikarla-Marie P, Kopetz S, Hawk ET et al (2018) Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev 37:439–454.  https://doi.org/10.1007/s10555-018-9755-8 CrossRefGoogle Scholar
  65. 65.
    Thun MJ, Jacobs EJ, Patrono C (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9:259–267.  https://doi.org/10.1038/nrclinonc.2011.199 CrossRefPubMedGoogle Scholar
  66. 66.
    Gay L, Felding-Habermann B (2011) Contribution of platelets to tumour metastases. Nat Rev Cancer 11:123–134.  https://doi.org/10.1038/nrc3004 CrossRefPubMedGoogle Scholar
  67. 67.
    Labelle M, Begum S, Hynes RO (2011) Direct signalling between platelets and cancer cells induces epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 20:576–590.  https://doi.org/10.1016/j.ccr.2011.09.009 CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Santilli F, Boccatonda A, Davì G (2016) Aspirin, platelets, and cancer: The point of view of the internist. Eur J Intern Med 34:11–20.  https://doi.org/10.1016/j.ejim.2016.06.004 CrossRefPubMedGoogle Scholar
  69. 69.
    Simon TG, Ma Y, Ludvigsson JF et al (2018) Association between aspirin use and risk of hepatocellular carcinoma. JAMA Oncol 4:1683–1690.  https://doi.org/10.1001/jamaoncol.2018.4154 CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Barnard ME, Poole EM, Curhan GC et al (2018) Association of analgesic use with risk of ovarian cancer in the nurses' health studies. JAMA Oncol 4:1675–1682.  https://doi.org/10.1001/jamaoncol.2018.4149 CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Jankowski JAZ, de Caestecker J, Love SB et al (2018) Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. Lancet 392:400–408.  https://doi.org/10.1016/S0140-6736(18)31388-6 CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DS, Anderson ML (2016) Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the US Preventive Services Task Force. Ann Intern Med 164:814–825.  https://doi.org/10.7326/M15-2117 CrossRefPubMedGoogle Scholar
  73. 73.
    Guirguis-Blake JM, Evans CV, Senger CA, Oconnor EA, Whitlock EP (2016) Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the US Preventive Services Task Force. Ann Intern Med 164:804–813.  https://doi.org/10.7326/M15-2113 CrossRefPubMedGoogle Scholar
  74. 74.
    Whitlock EP, Burda BU, Williams SB, Guirguis-Blake JM, Evans CV (2016) Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the US Preventive Services Task Force. Ann Intern Med 164:826–835.  https://doi.org/10.7326/M15-2112 CrossRefPubMedGoogle Scholar
  75. 75.
    Arnett DK, Blumenthal RS, Albert MA, et al (2019) 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Circulation 17:CIR0000000000000678Google Scholar
  76. 76.
    Eikelboom JW, Connolly SJ, Bosch J et al (2017) Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 377(14):1319–1330.  https://doi.org/10.1056/NEJMoa1709118 CrossRefGoogle Scholar
  77. 77.
    Bonaca MP, Bhatt DL, Cohen M et al (2015) Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372(19):1791–1800.  https://doi.org/10.1056/NEJMoa1500857 CrossRefPubMedGoogle Scholar
  78. 78.
    Patrono C, Baigent C (2019) Role of aspirin in primary prevention of cardiovascular disease. Nat Rev Cardiol.  https://doi.org/10.1038/s41569-019-0225-y CrossRefPubMedGoogle Scholar
  79. 79.
    Gatto L, Romagnoli E, Prati F (2019) Aspirin in primary prevention: who is the target? Eur Heart J 21(Suppl B):B54.  https://doi.org/10.1093/eurheartj/suz018 CrossRefGoogle Scholar
  80. 80.
    Tousoulis D (2019) What have we learned about using aspirin for primary prevention from the ASCEND and ARRIVE trials? Cardiovasc Res 115:e15–e16.  https://doi.org/10.1093/cvr/cvy281 CrossRefPubMedGoogle Scholar
  81. 81.
    Oikonomou EK, Marwan M, Desai MY et al (2018) Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. Lancet 392:929–939.  https://doi.org/10.1016/S0140-6736(18)31114-0 CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Sundström J, Hedberg J, Thuresson M, Aarskog P, Johannesen KM, Oldgren J (2017) Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide, population-based cohort study. Circulation 136:1183–1192.  https://doi.org/10.1161/circulationaha.117.028321 CrossRefPubMedGoogle Scholar
  83. 83.
    ETDRS Investigators (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus early treatment diabetic retinopathy study report 14. ETDRS Investigators. JAMA 268:1292–1300Google Scholar
  84. 84.
    Sacco M, Pellegrini F, Roncaglioni MC et al (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264–3272CrossRefGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna (SIMI) 2019

Authors and Affiliations

  1. 1.Department of Medicine and Aging, and Center of Aging Science and Translational Medicine (CESI-Met)“G. D’Annunzio” University Foundation School of MedicineChietiItaly

Personalised recommendations